Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.

Zidong Zhang is responsible for all aspects of financial management to support the growth of Novotech across Asia. Prior to joining Novotech, Dr. Zhang was CFO at Henlius Biotech, a Hong Kong-listed global biopharmaceutical company based in Shanghai, where he built and managed the finance team and played an integral role in the company’s initial public offering in 2019. Prior to that, Dr. Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector.

Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of around 500 employees across multiple sites in APAC. Andy holds an MBA from the Booth School of Business at the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.

Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.